Thierry de Baere
Institut Gustave Roussy
Publications 219
#1Gonzalo Recondo (Université Paris-Saclay)H-Index: 1
#2Laura MezquitaH-Index: 7
Last.Jean-Yves Scoazec (French Institute of Health and Medical Research)H-Index: 62
view all 0 authors...
Purpose: Lorlatinib is a third-generation ALK tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first and second-generation ALK inhibitors. Beside compound mutations in the ALK kinase domain, other resistance mechanisms driving lorlatinib resistance remain unknown. We aimed to characterize mechanisms of resistance to lorlatinib occurring in patients with ALK-rearranged lung cancer and design new therapeutic strategies in this setti...
#1Guillaume GravelH-Index: 3
#2Lambros TselikasH-Index: 7
Last.Thierry de BaereH-Index: 47
view all 11 authors...
Objectives To evaluate post-ablation MRI for the detection of incompletely treated spinal osseous metastases (SOM) after cryoablation and to propose a post-ablation imaging classification.
Purpose To evaluate the feasibility, efficacy and safety of sternal percutaneous fixation by internal cemented screw (FICS) using fluoroscopy and/or CT needle guidance.
#1Benjamin MoulinH-Index: 1
#2Lambros TselikasH-Index: 7
Last.Frederic DeschampsH-Index: 25
view all 11 authors...
Purpose To evaluate electromagnetic navigation system (ENS) for percutaneous fixation by internal cemented screw (FICS) under CT guidance.
#1S. Bonvalot (PSL Research University)H-Index: 46
#2Piotr Rutkowski (Curie Institute)H-Index: 47
Last.Marco RastrelliH-Index: 10
view all 42 authors...
Summary Background Pathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2–3 trial evaluated the safety and efficacy of the hafnium oxide (HfO 2 ) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. Methods Act.In.Sarc is a phase 2–3 randomised, multicentre, international trial. Adul...